|Slimming Drug Acomplia EMA say risks outweigh the benefits.|
|Written by Administrator|
|Tuesday, 28 October 2008|
Acomplia, which is an anti obesity drug, has been licensed in Europe since 2006. The European Medicines Agency (EMA) have found that it doubles the risk of psychiatric disorders. Depression can be one of the causes.
|Last Updated ( Thursday, 15 January 2009 )|
|< Prev||Next >|